

Datasheet: HCA233G

BATCH NUMBER 166598

Description:	HUMAN ANTI INFLIXIMAB
Specificity:	INFLIXIMAB
Other names:	Remicade
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD20436_hIgG1
Isotype:	IgG1
Quantity:	1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (kappa light chain) selected from the HuCAL phage display library and expressed in a human cell line. This product is supplied as a liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Source	HKB-11
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	Antibody concentration 1.0 mg/ml
Immunogen	Infliximab

Specificity

Human Anti-Infliximab Antibody, clone AbD20436_hlgG1, is an affinity matured anti-idiotypic antibody that specifically recognizes free infliximab but not infliximab bound to its target, tumor necrosis factor alpha (TNF α). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

This antibody inhibits the binding of infliximab to TNF α and can be used as a detection antibody in a pharmacokinetic (PK) bridging ELISA to measure free drug. As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

Infliximab (branded as Remicade) is a chimeric IgG1 kappa monoclonal antibody approved for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. This therapeutic antibody is directed against TNF α and acts by blocking the binding of TNF α to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.

[View a summary of all Anti-Infliximab Antibodies.](#)

Affinity

The intrinsic affinity of the monovalent of this antibody is $K_D=0.12$ nM as measured by real time, label-free molecular interaction analysis on immobilized Infliximab.

ELISA

This product may be used in a direct ELISA or as a bridging antibody in ADA assay development.

Protocol: [PK bridging ELISA to measure free drug](#)

Protocol: [ADA bridging ELISA](#).

References

1. Lee, M.W. *et al.* (2016) Comparison of infliximab drug measurement across three commercially available ELISA kits. [Pathology. Aug 23. pii: S0031-3025\(16\)39762-8. \[Epub ahead of print\]](#)

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee

12 months from date of despatch

Acknowledgements

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.

Remicade is a trademark of Janssen Biotech Inc. Inflectra is a trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp.

Health And Safety Information

Material Safety Datasheet documentation #10040 available at: <https://www.bio-rad-antibodies.com/SDS/HCA233G>

Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual .

Related Products

Recommended Useful Reagents

[HUMAN ANTI INFLIXIMAB \(HCA234\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M420944:230706'

Printed on 01 Mar 2024